Gabapentin Capsule
Product Images NDC 71335-3109

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-3109). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Cockcroft And Gault Equation (979787f3 7230 4586 862f 5c05686b8a43 01)

A drug facts panel showing a formula to calculate creatinine clearance (CLCr). The formula involves age (years), weight (kg), serum creatinine (mg/dL), and includes a multiplication factor of 0.85 for female patients.*

FDA Label Image

Image (979787f3 7230 4586 862f 5c05686b8a43 02)

Chemical structure depicting the molecular formula of gabapentin, the active ingredient in GABAPENTIN 300 mg capsules by Bryant Ranch Prepack.*

FDA Label Image

Figure 1. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 1 (979787f3 7230 4586 862f 5c05686b8a43 03)

A line graph showing mean pain scores over eight weeks comparing placebo and gabapentin 3600 mg/day groups. The x-axis represents weeks from baseline to week 8, and the y-axis represents mean pain scores from 0 to 10. The graph includes a 4-week dose titration period and a 4-week fixed dose period, illustrating a decrease in pain scores for gabapentin compared to placebo.*

FDA Label Image

Figure 2. Weekly Mean Pain Scores (observed Cases In Itt Population): Study 2 (979787f3 7230 4586 862f 5c05686b8a43 04)

Line graph depicting mean pain scores over a 7-week period comparing placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day. The x-axis shows weeks from baseline through week 7, and the y-axis displays mean pain scores from 0 to 10. The chart includes a 3-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Figure 3. Proportion Of Responders (patients With ≥ 50% Reduction In Pain Score) At Endpoint: Controlled Phn Studies (979787f3 7230 4586 862f 5c05686b8a43 05)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies,' comparing placebo (PBO) and gabapentin (GBP) doses in two studies. Study 1 shows 12% for placebo and 29% for GBP 3600 mg. Study 2 shows 14% for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance levels are noted (p ≤ 0.01, p < 0.001).*

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥ 12 Years Of Age With Partial Seizures (979787f3 7230 4586 862f 5c05686b8a43 06)

A scatter plot depicting percentage difference on the vertical axis versus daily dose in milligrams on the horizontal axis, comparing three studies labeled a, b, and c. Study a is represented by black squares, study b by gray squares, and study c by white squares, showing data points at doses approximately 600, 900, 1200, and 1800 mg.*

FDA Label Image

Label (Lbl713353109)

Gabapentin Capsules, USP 300 mg by Bryant Ranch Prepack. The label shows 500 capsules in the package, marked Rx only, child-resistant packaging. It includes storage instructions at controlled room temperature and a note to scan the QR code for prescribing information. Manufactured by Strides Pharma Science Limited.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.